$CC

HOSTETTER SHANE purchased $50K of CC

HOSTETTER SHANE (Chief Financial Officer) purchased 3,350 shares of Chemours Co (CC) at $14.94 on 2026-08-06.

Original reporting
SEC EDGAR · HOSTETTER SHANE
Published Aug 10, 2026, 8:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 10, 2026, 8:47 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$CC
Neutral
low confidence
Mentioned
$CC
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CCNeutralLow
01

Why it matters

A CFO open-market purchase of $50,049 worth of CC shares is disclosed, but there is no accompanying operational or financial update in the text.

02

Market read

Traders may note the insider buy as a small sentiment input, but the filing alone is unlikely to drive a major repricing without other catalysts.

03

What to watch

The filing states no pre-arranged 10b5-1 plan, but it still provides no context on motivation, timing constraints, or whether other insiders are buying/selling.

Relevance 4/10Novelty 3/10Timing: filed 2026-08-10 after-hours (Form 4 timestamp 16:30 ET)

Background

The article is a SEC Form 4 insider transaction disclosure for Chemours (CC).

Company-level read

Ticker impact

$CCNeutralLow confidence
Context

Chemours CFO Shane Hostetter filed a Form 4 showing an open-market purchase of 3,350 shares at $14.94 on 2026-08-06.

Expected impact

Limited near-term impact; any effect is likely sentiment-driven and small.

Evidence & confidence

Form 4 insider purchases can be informative, but this transaction size and lack of accompanying company-specific news make it unlikely to move the stock materially on its own.

Market effects

No clear sector read-through from a single CFO open-market purchase.

None indicated.

None indicated.

Counterpoint

Insider buys can be routine liquidity or diversification activity, and this Form 4 does not indicate a planned change in company outlook.

Key entities

  • Chemours Co

    Company whose insider transaction is disclosed via Form 4.

  • Shane Hostetter

    Chief Financial Officer reporting an open-market purchase.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CCMed

Why Chemours Plunged on Wednesday

Chemours (NYSE: CC) shares fell 18.7% after its Q2 earnings. The company reported slight revenue decline and adjusted EPS of $0.42, down 31% year over year, meeting expectations. Management cited lower Optane refrigerant sales due to supply-chain inventory and the wind-down of the SPS Capstone business. Full-year growth guidance remains 1% to 5%.

$CCMed

Why Chemours Plunged on Wednesday

Chemours (NYSE: CC) shares fell 18.7% after the company reported Q2 results. Revenue edged down and adjusted EPS fell 31% to $0.42, missing expectations. Lower Optane refrigerant sales and the prior wind-down of the SPS Capstone business weighed on results. Chemours still forecasts full-year growth of 1% to 5%.

$CCMedAI 8/10

The Chemours Company Reports Second Quarter Results

Chemours (NYSE: CC) reported Q2 2026 results: net sales about $1.6B, roughly flat year over year. Net loss attributable to Chemours was $274M ($1.81 per diluted share) versus $380M ($2.53) a year earlier. Adjusted net income was $64M ($0.42) and adjusted EBITDA $247M. Free cash flow rose 128% and net leverage fell to 4.4x. Chemours cited TiO2 pricing actions and APM Performance Solutions growth.

$CCMed

Chemours Co (CC): Results of Operations and Financial Condition

Chemours Co (CC) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 cc-ex99_1.htm EX-99.1 EX-99.1 EXHIBIT 99.1 The Chemours Company Reports Second Quarter Results Wilmington, Del., August 4, 2026 – The Chemours Company (“Chemours” or “the Company”) (NYSE: CC), a global chemistry company with leading market positions in Thermal & Special

$MMMHighAI 9/10

New York sues 3M, DuPont and other chemical companies over PFAS pollution By Investing.com

New York Attorney General Letitia James sued 3M, DuPont, Chemours, Corteva and EIDP over alleged PFAS (“forever chemicals”) contamination. The complaint says the firms knew since decades-old research that PFAS were toxic but concealed risks, continued selling PFAS products, and allegedly misled consumers. New York seeks cleanup funding, consumer warnings, advertising changes, and damages and penalties.